


**CS DIAGNOSTICS CORP.
CSDX**



QUARTERLY REPORT AND FINANCIALS

FOR THE PERIOD ENDING

June 30, 2025



Disclosure Statement Pursuant to the OTCQB Basic Disclosure Guidelines

CS DIAGNOSTICS CORP,
A Wyoming Corporation,
Stresemannallee 4b Neuss, Germany 41460
Telephone +49 (0)2131-151 08 71

<http://www.csdcorp.us>

info@csdcorp.us

SIC CODE: 2834


QUARTER REPORT For the Period Ending June 30, 2025

Outstanding Shares

The number of shares outstanding of our Common Stock was:

137,340,200 as of **June 30, 2025**

137,290,200 as of **December 31, 2024**



Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: No:

Change in Control

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the Issuer any names used by predecessor entities, along with the dates of the name changes.

The exact name of the issuer is **CS Diagnostics Corp.**

On September 25, 1996, the issuer was incorporated in the State of Nevada as D.W.C. Installations, Inc..

On December 27, 2002, the issuer name was changed to Children's Internet, Inc..

On February 18, 2015, the issuer name was changed to FlashZero Corp.

On May 31, 2022, the issuer name was changed to CS Diagnostics Corp..

On August 1, 2023, FINRA authorized the Corporation Action and the Articles were amended to change the name, **CS Diagnostics Corp.**


Current State and Date of Incorporation or Registration:

On October 15, 2010 the issuer was re- domiciled in the State of Wyoming. The issuer is in Good Standing in its domicile, Wyoming, and is designated status Active Business License.

Standing in this jurisdiction: **Active in Good Standing**

Prior Incorporation Information for the issuer and any predecessors during the past five years: **NONE.**

Describe any trading suspension orders issued by the SEC concerning the Issuer or its predecessors since inception: **NONE.**



List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On August 1, 2023, FINRA Notified the Issuer and its Transfer Agent that is has received the necessary documentation to process the below listed corporate action requested by FlashZero Corp (FZRO) and Transfer Online pursuant to FINRA Rule 6490. This Corporate Action included:

- 1 for 100,000 reverse split followed by a 200 for 1 forward split
- Name Change to: CS Diagnostics Corp.
- New CUSIP 33852L202 .

On September 4, 2023, CS Diagnostics Group finalized the agreement whereas CS Diagnostics Group sold and transferred the tangible, intangible and patents for the CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp.

The CS Diagnostics Group have obtained a valuation for the CS Protect-Hydrogel in amount greater than 960,000,000 Euro based on its discounted present commercial value. The valuation is supported, as contained in the final valuation by the 2018 purchase of the similar product by Boston Scientific for \$500,000,000 USD and further compensation based on the distribution revenues. CS Diagnostics Corp., based on this valuation, on September 27, 2023, the transfer agent, Transfer Online, issued 110,000,000 shares of the Issuer common stock to represent a payment of \$500,000,000 USD for the rights, patents and intellectual property of the CS Protect-Hydrogel product to the CS Diagnostics Group, its successor or assigns.

On July 29th 2024, FINRA processed a Form 211 relating to the initiation of priced quotations of CSDX, which means that the submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6432 and therefore has met the requirements under that rule to initiate a quotation for CSDX within four days of 07/29/2024. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.

On August 9th 2024, a shareholder resolution has been issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed is VP, Director and CFO, Mr. Thomas Migotsch remains a director and assigned as COO, Dr. Lauren Ugur and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary. It was agreed that Mr. Thomas Graus will receive compensation of \$ 72,000 during 2025.


The address(es) of the Issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Stresemann allée 4b Neuss 41460 Germany +49 (0)2131-151 08 71

Has the Issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:



If this Issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

NONE

1) Security Information

Transfer Agent

Name: **Transfer Online, Inc.**

Phone: +1-503-227-2950

Email: info@transferonline.com

Address: 512 SE Salmon St. Portland, OR 97214

Publicly Quoted or Traded Securities:

Trading symbol:

CSDX

Exact title and class of securities outstanding:

Common

CUSIP:

33852L103

Par or stated value:

0.00001

FEIN

20-1290331

Total shares authorized

250,000,000

as of date **June 30, 2025**

Total Common shares outstanding:

137,340,200

as of date **June 30, 2025**

Number of shares in the Public Float²:

9,075,301

as of date **June 30, 2025**

Total number of shareholders of record:


317

as of date **June 30, 2025**

CUSIP NUMBER

33852L202

All additional class(es) of publicly traded securities (if any): N/A



Other classes of authorized or outstanding equity securities:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:

Preferred Series A

CUSIP (if applicable):

N/A

Par or stated value:

\$0.00001

Total shares authorized:

1,000,000 as of date **June 30, 2025**

Total shares outstanding (if applicable):

10 as of date **June 30, 2025**

Total number of shareholders of record

1 as of date **June 30, 2025**

Exact title and class of the security:

Preferred Series B

CUSIP (if applicable):

N/A

Par or stated value:

\$0.00001

Total shares authorized:

20,000,000 as of date **June 30, 2025**

Total shares outstanding (if applicable):

19,992,575 as of date **June 30, 2025**

Total number of shareholders of record

18 as of date **June 30, 2025**

Exact title and class of the security:

Preferred Series C

CUSIP (if applicable):

N/A

Par or stated value:

\$0.00001

Total shares authorized:

4,000,000 as of date **June 30, 2025**


Total shares outstanding (if applicable):

0 as of date **June 30, 2025**

Total number of shareholders of record

0 as of date **June 30, 2025**

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.



Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1- For common equity, describe any dividend, voting and preemption rights.

Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval. There are no preemption rights for Common Equity Shareholders.

2- For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Preferred Series A

Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval.

The Series A Preferred Stock has voting rights equal to four times the sum of: a) the total number of shares of Common Stock which are issued and outstanding at the time of voting, plus b) the total number of shares of any other series of preferred stock which are issued and outstanding at the time of voting.

The holders of the Series A Preferred Stock shall no rights with respect to the conversion of the Series A Preferred Stock into an equivalent number of shares of Common Stock (the "Conversion Rights"), where the Series A Preferred Stock is defined as "Super Voting Stock".

The Liquidation Rights are:


Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount (the "Liquidation Preference") equal to the product of (i) the original amount paid by the holder thereof (the "Original Issue Price") for each share of Series A Preferred Stock owned by such holder as of the effective date of such liquidation (the "Liquidation Date"), multiplied by (ii) the number of shares of Series A Preferred Stock owned of record by such holder as of the Liquidation Date. (as adjusted for any combinations, splits, recapitalization and the like with respect to such shares in the manner set forth herein). It does not have any sinking fund provisions.

Preferred Series B

Currently there are no dividends. Dividends are subject to the Board of Directors discretion and approval.

The Series B Preferred Stock has same 1 vote for 1 shares as with the Common Share shareholders.

The Series B Preferred Stock has conversion of 20,000 shares of common stock for each share of



Preferred Series B stock with a maximum conversion of up to 9.9% of the total outstanding common stock. It does not have any sinking fund provisions.

The liquidation rights are

Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any stock ranking junior to the Preferred B Stock, the holders of the Preferred B Stock shall be entitled to be paid out of the assets of the Corporation an amount equal to \$1.00 per share or, in the event of an aggregate subscription by any single subscriber for Preferred B Stock in excess of \$100,000, \$.997 per share, (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares)(the "Preference Value"), plus all declared but unpaid dividends, for each share of Preferred B Stock held by them. After the payment of the full applicable Preference Value of each share of the Preferred B Stock as set forth herein, the remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Corporation's Common Stock.

3- Describe any other material rights of common or preferred stockholders.

None


4- Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

On March 24, 2023, the issuer and the majority shareholder, holding 100% of the Series A and in excess of 90% of Preferred Series B and 110,000,000 shares of common stock, approved and ratified An Amendment and Restatement of the Certificate of Designation of the Preferred Series A and Preferred Series B and the By-Laws of the Issuer in order to clarify the previous amendments to the Certificate of Designations and Amendments to the Articles of Incorporation. These Amendments and Restatement of the Certificate of Designations were filed with the Secretary of State of Wyoming.

3- Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.




A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

No: Yes: (If yes, you must complete the table below)

| Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> | | | | | *Right-click the rows below and select "Insert" to add rows as needed. | | | | |
|--|---|--|---------------------|---|--|--|---|---|---------------------------------|
| Date <u>January 1, 2023</u> | | | | | | | | | |
| Common: 135,287,214 Preferred A 10 Preferred B 9,989,000 | | | | | | | | | |
| Date of Transaction | Transaction type (e.g. new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of shares issued (\$/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance? (Yes/No) | Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed). | Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type. |
| 05-09-2022 | Issuance | 10,011,000 | PREFERRED Series B | 1,000 | No | PatientTrac Limited (See Note 1) | Pursuant to the Securities Purchase Agreement for services rendered, e.g. acquisition costs, payments and organization reinstatements | Restricted | 4(a)(2) |
| 08-01-2023 | Corporate Action Reverse split 1 to 100,000 and Forward Split 1 to 200 | -134,497,014 | Common | .00001 | No | Corporate Action all shareholders | Same | Restricted and Unrestricted | 4(a)(2) |



| | | | | | | | | | |
|---|----------|------------|--------|--------|----|------------------------------------|--------------------------|------------|---------|
| 09/27/2023 | Issuance | 65,000,000 | Common | \$4.54 | No | CS Diagnostics Pharma GmbH Note 2: | Asset Purchase Agreement | Restricted | 4(a)(2) |
| 09/27/2023 | Issuance | 20,000,000 | Common | \$4.54 | No | CS Interpharm LLC Note 2: | Asset Purchase Agreement | Restricted | 4(a)(2) |
| Shares Outstanding on Date of This Report: | | | | | | | | | |
| <u>Ending</u> <u>Balance</u> <u>Date</u> <u>June 30, 2025</u> | | | | | | | | | |
| Common: 137,340,200 Preferred A 10 Preferred B 19,992,575 | | | | | | | | | |

Note 1: PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees.

Note 2: The Beneficial Owner Thomas Fahrhoefer, Dubai, UAE


B. Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

N/A

Note: During the FINRA corporate action request, *supra*, On May 3, 2023, the Issuer Board of Directors and its Majority Shareholder pursuant to Wyoming Revised Statutes cancelled the remaining balance of the July 10, 2009 Promissory Note by and between the Issuer on David Lampel. A legal opinion has been issued and provided to the Issuer's PCAOB Auditors and the contingent liability, Promissory Note balance and interest, has been removed from the Issuer's financial statements.



4- Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.

- A. Summarize the Issuer's business operations (If the Issuer does not have current operations, state "no operations")

The publicly traded company CS Diagnostics Corp. is the sole owner of the property CS Protect-Hydrogel. CS Protect-Hydrogel, a hydrogel-based tissue spacer used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp.

The Issuer and its parent company, CS Diagnostics Pharma GmbH, and its affiliated company, CS Interpharm GT LLC, are actively engaged in proven operations in the Medical and Biotech industry.

- B. List any subsidiaries, parent company, or affiliated companies.

Parent Company


CS Diagnostics Pharma GmbH, Stresemannallee 4b Neuss, 41460 Germany

Affiliated Company

CS Interpharm General Trading LLC, 809-816 Bay Squair, Business Bay, Dubai, United Arab Emirates.

- C. Describe the Issuers' principal products or services.

CS Diagnostics Group is a pharmaceutical international wholesaler and manufacturer of medical technology. For more than 10 years its current management has been supplying national and international specialists, practices, clinics as well as ministries of health. In addition, we offer international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, we develop our own products with the aim of maximizing patient benefit.



5- Issuer's Facilities


The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the Issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the Issuer, give the location of the principal plants and other property of the Issuer and describe the condition of the properties.

If the Issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

**Headquarters: City of Neuss in Germany:
City of Bruckmühl in Germany
Dubai, United Arab Emirates**

| Name of Officer/Director or Control Person | Affiliation with Company (e.g. Officer/Director/Owner of more than 5%) | Residential Address (City / State Only) | Number of shares owned | Share type/class | Ownership Percentage of Class Outstanding | Note |
|--|--|---|--------------------------------|--------------------------------------|---|---|
| Thomas Fahrhoefer | President | Dubai, United Arab Emirates | 91,881,896 10 13,665,206 | Common Preferred A Preferred B | 67% 100% 68% | Beneficial Ownership (No shares in personal name) |
| Thomas J Migotsch | Chief Operational Officer | Rapperswil-Jona, Switzerland | 480.000 | N/A | .004% | |
| Mohammad EsSayed | Chief Financial Officer | Dubai, UAE | 0 | N/A | N/A | |
| Janel Luzana | Company Secretary | Dubai, UAE | 0 | N/A | N/A | |
| CS Diagnostics Pharma GmbH | More than 5% | Neuss, Germany | 74,855,800 10 7,924,180 | Common Preferred A Preferred B | 54.5% 100% 39.6% | Thomas Fahrhoefer, Dubai, UAE |
| CS Interpharm General Trading Co. LLC | More than 5% | Dubai, United Arab Emirates | 17,026,096 5,731,026 | Common Preferred B | 12.3% 28.6% | Thomas Fahrhoefer, Dubai, UAE |
| Association Continental de Reassurance NV | More than 5% | Antwerpen Belgium | 3,500,000 1,499,625 | Common Preferred B | 2.5% 7.5% | Adriaan Vangelabbeek Antwerpen, Belgium |
| Thomas Graus | More than 5% | Viganello Switzerland | 3,700,000 1,273,737 | Common Preferred B | 2.7% 6.4% | Thomas Graus Viganello, Switzerland |
| Antonio Santoli | More than 5% | Breganzona Switzerland | 3,800,000 1,273,737 | Common Preferred B | 2.7% 6.4% | Antonio Santoli Breganzona, Switzerland |



6- Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NO

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NO

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;


NO

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NO

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NO



6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NO

B. Describe briefly any material pending legal proceedings, other than ordinary B- routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

7- Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Mavacy, PLLC

15169 N. Scottsdale Rd.,
Suite 205,
Scottsdale, AZ 85254

Investor Relations/Marketing/Communications


Rosewood Reputation Limited

80 Coleman Street, ENG W1U 7LP
London, United Kingdom

Accounting/Auditing Firm

LAO Professionals

Suite 33, Hill Top Plaza, 13
Gwani Street, Zone 4, Wuse
Abuja 00234, Nigeria



Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

NONE

8- Disclosure & Financial Information

A. This Disclosure Statement was prepared by(name of individual):

| | |
|-------------------------|---------------------------------------|
| Name: | <u>Mohammad EsSayed</u> |
| Title: | <u>Chief Financial Officer</u> |
| Relationship to Issuer: | <u>VP, Director</u> |

B. The following financial statements were prepared in accordance with:


U.S. GAAP
 IFRS

C. The financial statements for this reporting period were prepared by (name of individual)³:

| | |
|-------------------------|--------------------------------|
| Name: | <u>Mohammad EsSayed</u> |
| Title: | <u>CFO</u> |
| Relationship to Issuer: | <u>VP, Director</u> |

Describe the qualifications of the person or persons who prepared the financial statements: Accounting firm preparing financial reporting and certified US Tax.

³ *The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.*



9- Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).


The certifications shall follow the format below:

I, Thomas Fahrhoefer, certify that:

1. I have reviewed this Annual Report and Disclosure Statement for Period Ending June 30, 2025 of CS Diagnostic Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 30, 2025

/s/ Thomas Fahrhoefer




Principal Financial Officer:

I, Mohammad EsSayed, certify that:

1. I have reviewed this Annual Report and Disclosure Statement for Period Ending June 30, 2025 of CS Diagnostic Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 30, 2025

/s/ Mohammad EsSayed




CS DIAGNOSTICS CORP

FINANCIAL STATEMENTS

FOR PERIOD ENDING

June 30, 2025

BALANCE SHEET STATEMENT
STATEMENT CASH FLOWS
INCOME STATEMENT
STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY
FINANCIAL NOTES



CS DIAGNOSTICS CORP.
OTCQB-CSDX

INDEX TO FINANCIAL STATEMENTS


Balance Sheets as of June 30, 2025, and December 31, 2024

Statements of Operations for the Three months and Six months period ended June 30, 2025, and June 30, 2024

Statements of Stockholders' Equity for Six months period ended June 30, 2025, and December 31, 2024

Statements of Cash Flows for the Six months period ended June 30, 2025, and June 30, 2024

Notes to the Financial Statements



CS DIAGNOSTICS CORP. CSDX


BALANCE SHEET

FOR THE PERIOD ENDED June 30 2025

| | March 31, 2025 | December 31, 2024 |
|--|----------------------|----------------------|
| | <i>Un-Audited</i> | <i>Audited</i> |
| <u>Assets</u> | | |
| Current Assets | | |
| Cash | 24,966 | 501 |
| Other Receivables | 31,715 | - |
| Total Current Assets | \$56,681 | \$501 |
| Intangible Assets | 499,400,000 | 499,400,000 |
| Total Assets | \$499,456,681 | \$499,400,501 |
| <u>Liabilities and Stockholders' Deficit</u> | | |
| Current Liabilities | | |
| Account Payables | - | 1,428 |
| Non-current liabilities | - | - |
| Total Liabilities | \$0 | \$1,428 |
| Shareholder's Deficit | | |
| Common stock, \$0.00001 par value; 250,000,000 shares authorized, 137,340,200 shares issued and outstanding as of March 31, 2025 | 1,373 | 1,373 |
| Preferred stock Series A, \$0.00001 par value; 5,000 shares authorized, 10 shares issued and outstanding as of March 31, 2025 | - | - |
| Preferred stock Series B, \$0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of March 31, 2025 | 2,000 | 2,000 |
| Preferred stock Series C, \$0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2025 | 40 | - |
| Additional paid-in capital | 504,163,629 | 504,163,629 |
| Accumulated deficit | -4,710,361 | -4,767,928 |
| Total Stockholders' Deficit | \$499,456,681 | \$499,399,073 |
| Total Liabilities and Stockholders' Deficit | \$499,456,681 | \$499,400,501 |

The accompanying notes are an integral part of these financial statements.


This is an unaudited financial statement, can be subject to minor changes upon Auditor review



STATEMENT OF OPERATIONS
FOR THE PERIOD ENDED JUNE 30, 2025

| | For The Three Months Ended June 30 2025 | For The Three Months Ended June 30 2024 | For The Six Months Ended June 30 2025 | For The Six Months Ended June 30 2024 |
|---|---|---|---|---|
| Revenue | 25,500 | 45,159 | 95,920 | 98,417 |
| Revenue | \$25,500.00 | \$45,159.00 | \$95,920.00 | \$98,417.00 |
| <i>Operating Expenses</i> | | | | |
| Professional Fee | 520 | 40,709 | 17,039 | 85,264 |
| General & Administrative Expenses | 14 | 101 | 21,848 | 241 |
| Total Operating expenses | 534 | 40,810 | 38,887 | 85,505 |
| Income/(loss) from Operations | \$24,966 | \$4,349 | \$57,033 | \$12,912 |
| Other Income / (Expense) | - | | | |
| Debt Written off | | | | |
| Net Income / (loss) | \$24,966 | \$4,349 | \$57,033 | \$12,912 |
| Basic and diluted loss per share | 0.00 | 0.00 | 0.00 | 0.00 |
| basic and diluted loss weighted average shares | 137,430,200 | 123,290,200 | 137,430,200 | 123,290,200 |

*The accompanying notes are an integral part of these financial statements.
 This is an unaudited financial statement, can be subject to minor changes upon Auditor review*



CS DIAGNOSTICS CORP.


STATEMENT OF STOCKHOLDERS (DEFICIT)

FOR THE PERIOD ENDED June 30, 2025

| | Preferred Stock B | | Preferred Stock C | | Common Stock | | Additional | Accumulated | Total |
|--|-------------------|----------------|-------------------|------------|--------------------|----------------|----------------------|---------------------|----------------------|
| | Shares | Amount | Shares | Amount | Shares | Amount | | | |
| Balance, January 1, 2024 | 20,000,000 | \$2,000 | \$0 | \$0 | 110,790,200 | \$1,018 | \$504,173,122 | -\$4,798,689 | \$499,407,451 |
| Reversed Stock Split | - | - | - | - | - | - | - | - | - |
| Shares Issued/Converted | -1,325 | \$0 | \$0 | \$0 | 26,500,000 | \$355 | -\$9,493 | - | -\$9,138 |
| Net income (loss) for the year | - | - | - | - | - | - | \$761 | \$761 | \$761 |
| Balance, December 31, 2024 | 19,998,675 | \$2,000 | \$0 | \$0 | 137,290,200 | \$1,373 | \$504,163,629 | -\$4,767,928 | \$499,399,073 |
| Balance, March 31, 2025 | 19,992,575 | 2,000 | 4,000,000 | 40 | 137,340,200 | 1,373 | 504,163,629 | -4,735,681 | 499,431,361 |
| Shares Issued/Converted | | | | | | | | | |
| Net income (loss) for the period ended June 30, 2025 | | | | | | | \$25,500 | \$25,500 | \$25,500 |
| Shares Issued in acquisition of Assets | | | | | | | | | |
| Balance, June 30, 2025 | 19,992,575 | 2,000 | 4,000,000 | 40 | 137,340,200 | 1,373 | 504,163,629 | -4,710,361 | 499,456,681 |

The accompanying notes are an integral part of these financial statements.

This is an unaudited financial statement, can be subject to minor changes upon Auditor review



CS DIAGNOSTICS CORP.
STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED June 30, 2025

For the Six Months Ended June 30

2025 2024

Cash flows from operating activities

| | | |
|--|--------|-------|
| Net profit/ (loss) | 24,966 | 4,349 |
| Adjustment to reconcile net loss to net cash used in operating activities | | |
| Changes in assets and liabilities | | |
| Other Receivables | 31,715 | 8,564 |
| Account payables | 0 | -613 |

Net cash used in operating activities **\$56,681** **\$12,300**

Cash flows from investing activities

| | | |
|--|-----------------------|-----------------------|
| Intangible Asset | -499,444,401 | -499,444,401 |
| Net cash provided by Investing activities | -\$499,444,401 | -\$499,444,401 |


Cash flows from financing activities

| | | |
|----------------------------|-------------|-------------|
| Additional Capital Paid Up | 499,444,401 | 499,444,401 |
| Loan forgiven | - | - |

Net cash provided by financing activities **\$499,444,401.00** **\$499,444,401.00**

| | | |
|----------------------------------|-----------------|-----------------|
| Net increase /(decrease) in cash | 56,681 | 12,300 |
| Cash beginning of period | 730 | 8,767 |
| Cash end of period | \$57,411 | \$21,067 |

*The accompanying notes are an integral part of these financial statements.
This is an unaudited financial statement, can be subject to minor changes upon Auditor review*



C S DIAGNOSTICS CORP
Notes to the Financial Statements
March 31, 2025, and December 31, 2024

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United States, is an United States based Corporation. Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.

On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for an amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200.

On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.



Concentrations of Credit Risk

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

Cash and Cash Equivalents

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.


The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

Income Taxes

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.



We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

Net income (loss) per common share

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended June 30, 2025 and 2024, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti-dilution due to the net loss incurred by the Company


Recent Accounting Pronouncements

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of \$(4,710,361) at June 30, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.



NOTE 4 – INCOME TAXES

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

Net deferred tax assets consist of the following components as of:

| | June 30, 2025 | December 31, 2024 |
|--|------------------|----------------------|
| Federal income tax benefit attributable to: | | |
| Current Operations | \$ — | \$ — |
| Less: valuation allowance | — | — |
| Net provision for Federal income taxes | \$ — | \$ — |

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

| | June 30, 2025 | December 31, 2024 |
|--|------------------|----------------------|
| Deferred tax asset attributable to: | | |
| Net operating loss carryover | \$ — | \$ — |
| Less: valuation allowance | — | — |
| Net deferred tax asset | \$ — | \$ — |

At March 31, 2025, the Company had net operating loss carry forwards of approximately \$(4,710,361) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the June 30 2025, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

NOTE 5 – SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.